Healios K.K. (HLOSF)
USD 1.35
(0.0%)
USD 1.35
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.48 Billion JPY | 9292.38% |
| 2022 | 37.13 Million JPY | -17.14% |
| 2021 | 44.81 Million JPY | 15.8% |
| 2020 | 38.7 Million JPY | -0.54% |
| 2019 | 38.91 Million JPY | -99.22% |
| 2018 | 4.98 Billion JPY | 119.39% |
| 2017 | 2.27 Billion JPY | -33.3% |
| 2016 | 3.4 Billion JPY | 41473.88% |
| 2015 | 8.19 Million JPY | -98.97% |
| 2014 | 799.06 Million JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 712 Million JPY | -27.74% |
| 2024 Q1 | 6.5 Million JPY | -15.25% |
| 2023 Q2 | 4.7 Million USD | -16.67% |
| 2023 FY | 3.48 Billion JPY | 9292.38% |
| 2023 Q4 | 8.22 Million USD | 82.42% |
| 2023 Q1 | 5.64 Million USD | -28.94% |
| 2023 Q3 | 4.51 Million USD | -4.12% |
| 2022 Q2 | 11.35 Million JPY | -99.16% |
| 2022 Q4 | 7.94 Million JPY | 22.62% |
| 2022 Q3 | 6.47 Million JPY | -42.94% |
| 2022 Q1 | 1.34 Billion JPY | -7.35% |
| 2022 FY | 37.13 Million JPY | -17.14% |
| 2021 FY | 44.81 Million JPY | 15.8% |
| 2021 Q2 | 8.82 Million JPY | -27.8% |
| 2021 Q4 | 1.45 Billion JPY | 5.74% |
| 2021 Q1 | 12.21 Million JPY | -99.03% |
| 2021 Q3 | 1.37 Billion JPY | 15499.82% |
| 2020 Q1 | 937 Million JPY | -24.74% |
| 2020 FY | 38.7 Million JPY | -0.54% |
| 2020 Q3 | 1.08 Billion JPY | 17.42% |
| 2020 Q2 | 924 Million JPY | -1.39% |
| 2020 Q4 | 1.26 Billion JPY | 16.5% |
| 2019 Q4 | 1.24 Billion JPY | 15.17% |
| 2019 Q3 | 1.08 Billion JPY | 9.75% |
| 2019 Q1 | 1.03 Billion JPY | 0.19% |
| 2019 Q2 | 985 Million JPY | -4.55% |
| 2019 FY | 38.91 Million JPY | -99.22% |
| 2018 Q1 | 553 Million JPY | 0.49% |
| 2018 Q3 | 732 Million JPY | -73.36% |
| 2018 Q2 | 2.74 Billion JPY | 396.93% |
| 2018 FY | 4.98 Billion JPY | 119.39% |
| 2018 Q4 | 1.03 Billion JPY | 40.71% |
| 2017 Q1 | 508 Million JPY | 7.64% |
| 2017 FY | 2.27 Billion JPY | -33.3% |
| 2017 Q2 | 451.28 Million JPY | -11.16% |
| 2017 Q4 | 550.3 Million JPY | -36.18% |
| 2017 Q3 | 862.28 Million JPY | 91.07% |
| 2016 Q2 | 506.75 Million JPY | -76.24% |
| 2016 FY | 3.4 Billion JPY | 41473.88% |
| 2016 Q4 | 471.94 Million JPY | 1.69% |
| 2016 Q3 | 464.1 Million JPY | -8.42% |
| 2016 Q1 | 2.13 Billion JPY | 470.32% |
| 2015 Q2 | 317.68 Million JPY | 27.02% |
| 2015 Q4 | 374.03 Million JPY | 80.36% |
| 2015 Q3 | 207.37 Million JPY | -34.72% |
| 2015 Q1 | 250.09 Million JPY | 0.0% |
| 2015 FY | 8.19 Million JPY | -98.97% |
| 2014 FY | 799.06 Million JPY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | -3917.975% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -70804.06% |
| SQZ Biotechnologies Company | 85.61 Million USD | -3972.694% |
| Evofem Biosciences, Inc. | 29.55 Million USD | -11699.141% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | -9259.649% |
| Mesoblast Limited | 5.9 Million USD | -58981.667% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -232072.736% |
| Genus plc | 147.7 Million USD | -2260.867% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -39618.727% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -259824.192% |
| Marizyme, Inc. | 19.23 Million USD | -18023.859% |
| ContraFect Corporation | 56.88 Million USD | -6029.48% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -41715.565% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -78994.113% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -235706.951% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -119471.982% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -124866.089% |
| MultiCell Technologies, Inc. | 567.42 USD | -614535869.828% |
| Accustem Sciences Inc. | 3.74 Million USD | -92975.548% |
| RVL Pharmaceuticals plc | 85.94 Million USD | -3957.246% |
| EV Biologics, Inc. | 531.96 Thousand USD | -655397.949% |
| Q BioMed Inc. | 3.43 Million USD | -101365.739% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | -14008.841% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -894998.648% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -132610.592% |
| Biomind Labs Inc. | 994.18 Thousand USD | -350640.609% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | -1446.403% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -51805.213% |
| Skye Bioscience, Inc. | 13.54 Million USD | -25638.971% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -170105.081% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 13948100.0% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -69058.46% |
| IMV Inc. | 37.7 Million USD | -9147.077% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | -21679.815% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -189917.411% |
| GB Sciences, Inc. | 1.42 Million USD | -245375.389% |
| Alpha Cognition Inc. | 9.7 Million USD | -35827.708% |
| HST Global, Inc. | 140.9 Thousand USD | -2474581.882% |
| CSL Limited | 3.44 Billion USD | -1.102% |
| Halberd Corporation | 74.84 Thousand USD | -4659048.606% |
| Enzolytics Inc. | 2.17 Million USD | -159890.31% |
| Resverlogix Corp. | 12.71 Million USD | -27330.774% |
| Affymax, Inc. | 39.38 Million USD | -8753.4% |
| SYBLEU INC | 160.87 Thousand USD | -2167407.894% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -95415.745% |
| argenx SE | 1.53 Billion USD | -127.384% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | -5970.682% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -333903.831% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -220686.334% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -102308.855% |
| AVAX Technologies, Inc. | 7.31 Million USD | -47600.056% |
| Zenith Capital Corp. | 8.94 Million USD | -38891.39% |
| Genscript Biotech Corporation | 825.34 Million USD | -322.491% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -20015972.556% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -141918.322% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -2033029.457% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | -3410.514% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -198061.255% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | -176722.509% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -186933.69% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | -31987.973% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -181428.924% |
| BioStem Technologies, Inc. | 22.97 Million USD | -15077.498% |
| ONE Bio Corp. | 6.44 Million USD | -54013.26% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -1921270.912% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -261014.202% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -309880.354% |
| Agentix Corp. | 1.37 Million USD | -254099.726% |
| LadRx Corporation | 3.81 Million USD | -91379.307% |
| Cell Source, Inc. | 4.32 Million USD | -80517.828% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -839172.262% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -377481.185% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -377481.185% |
| NovAccess Global Inc. | 2.46 Million USD | -141259.459% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -144893.584% |
| Itoco Inc. | 919.14 Thousand USD | -379275.135% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -82171.34% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -311517.516% |
| Kadimastem Ltd | 2.41 Million USD | -144582.073% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -1332209.362% |
| CytoDyn Inc. | 18.05 Million USD | -19210.001% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -13854244.63% |
| Mobile Lads Corp. | 554.54 Thousand USD | -628702.66% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -1584338.245% |
| Qrons Inc. | 643.67 Thousand USD | -541631.334% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -245499.355% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -156276.198% |
| Rebus Holdings, Inc. | 664 Thousand USD | -525050.602% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -191881.589% |
| International Stem Cell Corporation | 5.27 Million USD | -66054.43% |
| Bioxytran, Inc. | 3.82 Million USD | -91179.21% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -6623888.45% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -17140931.313% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | -9515.066% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -215412.979% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -473783.411% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -111986.146% |
| Neutra Corp. | 243.82 Thousand USD | -1430047.526% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -19874.795% |
| PureTech Health plc | 144.59 Million USD | -2311.53% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | -16918.151% |
| IXICO plc | 4.7 Million USD | -73981.156% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -39538.513% |
| Gelesis Holdings, Inc. | 117.74 Million USD | -2861.409% |
| CSL Limited | 3.89 Billion USD | 10.429% |
| Cellectis S.A. | 97.32 Million USD | -3483.025% |